The government has pledged £ 37 million for data-driven initiatives to boost the UK’s life sciences and genomics industries.
The funding will be used to provide better research, treatment, care and improve clinical decision-making, according to a statement from the Department of Health and Social Care (DHSC).
Genomics England projects that support the implementation of the Genome UK strategy will receive £ 17 million, while the remaining £ 20 million will be invested in projects to “leverage UK health data for research into life sciences ”to make the UK“ the most advanced and enabled clinical research for environmental data in the world ”.
Genomics England will use funding to explore the public attitude and potential value of newborn sequencing, contributing to the rise of ethnic minority data in genomic cohorts and datasets and supporting a next-generation approach to diagnosis of cancer.
New support for the UK Functional Genomics Initiative also aims to drive new innovative approaches to improving our understanding of how genetic changes cause disease.
Speaking at the ABPI Annual Conference today, Health Secretary Matt Hancock said: “Today I am proud to outline the next steps with a £ 20 million investment in the new search, recruitment and monitoring service. data-based trials.
“I am determined to make it faster and easier to set up and deliver the high-power clinical trials we need, more than that, the trials will be better with data prepared for R&D, to strengthen their power to increase the diversity of participants .
“Thus, bring safer and faster medicines to the market, from cancer to cardiovascular, through all the diseases known to humanity. Taken together, all of this means better research, better treatment, better clinical decision making and more lives saved and lives improved, that is the mission of the life sciences. ”
Hancock also stressed the need to build on the achievements of the life sciences industry achieved during the Covid-19 pandemic, including the deployment of the vaccination program and the launch of an antiviral working group.
“Facing Covid has been a global mission, but there are so many other noble missions that are still ahead. I’m sure you can think of the ones you’re most focused on. Fighting cancer. Treatments for dementia. Prevent heart disease, ”he said.
“It’s no longer about getting back to where we were, but about charting a new and better course, where we learn the lessons of the pandemic and recover better, to transform the UK into a superpower in the life sciences.”